In another study, elevated levels of PRMT5 were shown to reduce the tumour‐suppressor activity of PDCD4 in primary breast tumours by methylating its N‐terminal arginine residues, resulting in reduced patient survival.24 This evidence concerns the gene PDCD4 and breast neoplasm.